Butyric Acid

Butyric Acid

SCHEMBL4155200

CC(C)N(CCO)S(=O)(=O)c1ccc2[nH]c(=O)c3[nH]ccc3c2c1.CCCC(=O)O

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.40
TP53 P04637 1/20 0.39
KDM4E B2RXH2 4/20 0.39
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 1/20 0.34
BRAF P15056 5/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 2/20 0.33
USP2 O75604 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
KEAP1 Q14145 1/20 0.32
NFE2L2 Q16236 1/20 0.32
VCAM1 P19320 1/20 0.32
ADRB2 P07550 1/20 0.32
RECQL P46063 1/20 0.32
PARP1 P09874 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL4155289 0.90 RXFP1 (0.47) RXFP1TP53KDM4EPOLBSMN1; SMN2
Butyric Acid SCHEMBL4155243 0.85 KDM4E (0.39) RXFP1TP53KDM4EPOLBSMN1; SMN2
Butyric Acid SCHEMBL4165214 0.85 ALOX5AP (0.36) TP53MEN1KMT2A
Butyric Acid SCHEMBL4162647 0.84 RXFP1 (0.42) RXFP1TP53KDM4EPOLBSMN1; SMN2
Butyric Acid SCHEMBL4163999 0.83 KDM4E (0.47) RXFP1TP53KDM4EPOLBSMN1; SMN2
Butyric Acid SCHEMBL4169890 0.83 KDM4E (0.59) RXFP1TP53KDM4EPOLBGAA
Butyric Acid SCHEMBL4162712 0.82 RXFP1 (0.35) RXFP1TP53KDM4EMAPT
Butyric Acid SCHEMBL4156383 0.81 KDM4E (0.45) RXFP1TP53KDM4EPOLBSMN1; SMN2
Butyric Acid SCHEMBL4160575 0.81 KDM4E (0.44) RXFP1TP53KDM4EPOLBSMN1; SMN2
Butyric Acid SCHEMBL4157688 0.80 KDM4E (0.51) RXFP1TP53KDM4EPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 RXFP1 3999/4885TP53 637/4885KDM4E 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.